Insights on the Recombinant Proteins Global Market to 2030 - Declining Cost of Therapeutics Recombinant Proteins and Advent of Biosimilars Presents Opportunities

News provided by

Sep 28, 2022, 06:04 ET

DUBLIN, Sept. 28, 2022 /PRNewswire/ -- The "Recombinant Proteins Market Size, Share & Trends Analysis Report by Host Cell (Insect Cells, Mammalian), by Application (Research, Therapeutics), by Product & Services, by End-user, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

The global recombinant proteins market size is expected to reach USD 5.09 billion by 2030, registering a CAGR of 12.0% over the forecast period, according to this report.

Diseases like multiple sclerosis, neutropenia, cerebral apoplexy, anemia, and others, as well as dwarfism, are becoming more common, which is driving up the demand for recombinant protein drugs. Furthermore, the industry is anticipated to expand due to the increased development and research on biologics, which, in turn, are significantly boosting global industry growth. The focus on the development of biosimilars, biologics, and recombinant proteins has increased owing to a rise in the incidence and prevalence of cancer and the expansion of research & development activity.

According to the American Cancer Society, in 2022, there will be 1.9 million new cases of cancer and 609,360 cancer-related deaths. In addition, the expanding application of recombinant proteins in clinical diagnostic methods including ELISA, Western Blotting, and Immunohistochemistry (IHC) is anticipated to fuel market expansion.

Due to factors including rising R&D spending, an increase in the number of cancer patients, and the desire for novel & tailored therapies, the global industry is anticipated to expand significantly during the forecast period. Research activity in recombinant protein space has increased in response to the COVID-19 pandemic as a result of efforts to comprehend the dynamics of the virus. The production of recombinant proteins has increased significantly, along with tailored treatment.

In addition, research funding is predicted to become more readily available along with an increase in demand for and production of recombinant proteins, particularly those immune response proteins associated with COVID-19. Therefore, positive effects have been seen for the companies offering products specifically made for COVID-19.

Recombinant protein is viewed as a modified version of natural protein that can be produced in a number of ways to improve protein output, create useful commercial goods, and alter gene sequences. The rise in pharmaceutical firms' R&D expenditures, high incidence of chronic illnesses, an increase in the number of regulatory requirements, and the ongoing need to reduce viral infections are the main drivers of the global industry.

Over the projected period, the global industry is anticipated to be driven by technological advancements in the synthesis of recombinant proteins.

For instance, in June 2022, according to the data produced by the National Center for Biotechnology Information, new breeding techniques, such as CRISPR/Cas9, TALEN, and Zinc Finger mediated, as well as transgenic or cis-genic techniques, are emerging technologies that may make it easier for in vitro genetic editing or manipulation of the genes to be approved.

In addition, industry participants are anticipated to invest in the region due to the aging population, rising income levels, better healthcare infrastructure, rising healthcare spending, and the advantages of low-cost manufacturing in developing nations, thereby propelling market growth.

Recombinant Proteins Market Report Highlights

By product & services, the product segment accounted for the largest revenue share in 2021. The demand is increasing globally due to the need for recombinant protein products in biomedical research and increased funding for R&D in the fight against cancer
The therapeutics application segment held the maximum revenue share in 2021 due to the prevalence of various diseases, such as metabolic disorders, cancer, genetic disorders, and immune diseases
The pharma & biotech companies end-user segment led the global industry in 2021 due to the increasing investments by key market players in their R&D segment to increase research productivity and grow their offerings for revenue generation
Mammalian systems are widely used in the production of recombinant proteins, thus, this segment accounted for the largest revenue share in 2021
North America was the dominant region in 2021 due to an increase in the incidence of chronic diseases, use of cutting-edge treatments, presence of key players, and rise in healthcare spending in the region
Asia Pacific is expected to grow at the fastest CAGR over the projected period due to an uptick in R&D activity, an increase in disposable incomes, and a better understanding of protein therapies among patients
India and China are additionally anticipated to see rapid growth in the Asia-Pacific region

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Market Variables, Trends & Scope
3.1 Market Trends & Outlook
3.2 Market Segmentation And Scope
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Growing Research Activities For Drug Development And Precision Medicine
3.3.1.2 Rising Adoption Of Biologics And Biosimilars
3.3.1.3 Increasing Investments In Research & Development Activities
3.3.2 Market Restraint Analysis
3.3.2.1 Regulatory And Safety Concerns With Protein Production
3.3.2.2 Dearth Of Skilled Personnel And Expertise
3.3.3 Market Opportunity Analysis
3.3.3.1 Declining Cost Of Therapeutics Recombinant Proteins And Advent Of Biosimilars
3.3.3.2 Innovative Techniques Can Decrease The Recombinant Protein Production Cost
3.4 Business Environment Analysis Tools
3.4.1 Swot Analysis, By Pest
3.4.2 Porter's Five Forces Analysis
3.5 Penetration & Growth Prospect Mapping For Product, 2021
3.6 Recombinant Proteins Market: Covid-19 Impact Analysis

Chapter 4 Product Segment Analysis
4.1 Recombinant Proteins Market: Product Movement Analysis
4.2 Product
4.2.1 Global Recombinant Proteins Product Market, 2018 - 2030 (USD Million)
4.2.2 Cytokines &Growth Factors
4.2.2.1 Global Cytokines & Growth Factors Market, 2018 - 2030 (USD Million)
4.2.2.1.1 Interferons
4.2.2.1.1.1 Global Interferons Market, 2018 - 2030 (USD Million)
4.2.2.1.2 Interleukins
4.2.2.1.2.1 Global Interleukins Market, 2018 - 2030 (USD Million)
4.2.2.1.3 Others
4.2.2.1.3.1 Others Cytokines & Growth Factors Market, 2018 - 2030 (USD Million)
4.2.3 Antibodies
4.2.3.1 Global Antibodies Market, 2018 - 2030 (USD Million)
4.2.4 Immune Checkpoint Proteins
4.2.4.1 Global Immune Checkpoint Proteins Market, 2018 - 2030 (USD Million)
4.2.5 Virus Antigens
4.2.5.1 Global Virus Antigens Market, 2018 - 2030 (USD Million)
4.2.6 Enzymes
4.2.6.1 Global Enzymes Market, 2018 - 2030 (USD Million)
4.2.6.1.1 Kinases
4.2.6.1.1.1 Global Kinases Market, 2018 - 2030 (USD Million)
4.2.6.1.2 Metabolic Enzymes
4.2.6.1.2.1 Global Metabolic Enzymes Market, 2018 - 2030 (USD Million)
4.2.6.1.3 Others
4.2.6.1.3.1 Others Enzymes Market, 2018 - 2030 (USD Million)
4.2.7 Recombinant Regulatory Proteins
4.2.7.1 Global Recombinant Regulatory Proteins Market, 2018 - 2030 (USD Million)
4.2.8 Hormones
4.2.8.1 Global Hormones Market, 2018 - 2030 (USD Million)
4.2.9 Others
4.2.9.1 Others Product Market, 2018 - 2030 (USD Million)
4.3 Production Services
4.3.1 Global Recombinant Proteins Production Services Market, 2018 - 2030 (USD Million)

Chapter 5 Application Segment Analysis
5.1 Recombinant Proteins Market: Application Movement Analysis
5.2 Drug Discovery & Development
5.2.1 Global Drug Discovery & Development, 2018 - 2030 (USD Million)
5.3 Therapeutics
5.3.1 Global Therapeutics Market, 2018 - 2030 (USD Million)
5.3.2 Biologics
5.3.2.1 Global Biologics Market, 2018 - 2030 (USD Million)
5.3.3 Vaccines
5.3.3.1 Global Vaccines Market, 2018 - 2030 (USD Million)
5.3.4 Cell & Gene Therapies
5.3.4.1 Global Cell & Gene Therapies Market, 2018 - 2030 (USD Million)
5.3.5 Others
5.3.5.1 Others Therapeutics Market, 2018 - 2030 (USD Million)
5.4 Research
5.4.1 Global Research Market, 2018 - 2030 (USD Million)
5.5 Other
5.5.1 Other Application Market, 2018 - 2030 (USD Million)

Chapter 6 End-User Segment Analysis
6.1 Recombinant Proteins Market: End-User Movement Analysis
6.2 Pharmaceutical & Biotechnology Companies
6.2.1 Global Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
6.3 Academic & Research Institutes
6.3.1 Global Academic & Research Institutes Market, 2018 - 2030 (USD Million)
6.4 Diagnostic Laboratories
6.4.1 Global Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
6.5 Others
6.5.1 Other End-Users, 2018 - 2030 (USD Million)

Chapter 7 Host-Cells Segment Analysis
7.1 Recombinant Proteins Market: Host-Cells Movement Analysis
7.2 Mammalian Systems
7.2.1 Global Mammalian Systems Market, 2018 - 2030 (USD Million)
7.3 Insects Cells
7.3.1 Global Insects Cells Market, 2018 - 2030 (USD Million)
7.4 Yeast & Fungi
7.4.1 Global Yeast & Fungi Market, 2018 - 2030 (USD Million)
7.5 Bacterial Cells
7.5.1 Global Bacterial Cells Market, 2018 - 2030 (USD Million)
7.6 Others
7.6.1 Other Host-Cells, 2018 - 2030 (USD Million)

Chapter 8 Regional Outlook

Chapter 9 Competitive Landscape
9.1 Strategy Framework
9.2 Market Participation Categorization
9.3 Company Profiles
9.3.1 Thermo Fisher Scientific, Inc.
9.3.1.1 Company Overview
9.3.1.2 Financial Performance
9.3.1.3 Product Benchmarking
9.3.1.4 Strategic Initiatives
9.3.2 Abcam plc
9.3.2.1 Company Overview
9.3.2.2 Financial Performance
9.3.2.3 Product/Service Benchmarking
9.3.2.4 Strategic Initiatives
9.3.3 Bio-Rad Laboratories, Inc.
9.3.3.1 Company Overview
9.3.3.2 Financial Performance
9.3.3.3 Product/Service Benchmarking
9.3.3.4 Strategic Initiatives
9.3.4 Bio-Techne Corporation
9.3.4.1 Company Overview
9.3.4.1.1 R&D Systems
9.3.4.2 Financial Performance
9.3.4.3 Product Benchmarking
9.3.4.4 Strategic Initiatives
9.3.5 Merck KGaA
9.3.5.1 Company Overview
9.3.5.2 Financial Performance
9.3.5.3 Product Benchmarking
9.3.5.4 Strategic Initiatives
9.3.6 GenScript Biotech Corporation
9.3.6.1 Company Overview
9.3.6.2 Financial Performance
9.3.6.3 Product Benchmarking
9.3.6.4 Strategic Initiatives
9.3.7 RayBiotech Life, Inc.
9.3.7.1 Company Overview
9.3.7.2 Financial Performance
9.3.7.3 Product Benchmarking
9.3.7.4 Strategic Initiatives
9.3.8 Proteintech Group, Inc.
9.3.8.1 Company Overview
9.3.8.2 Financial Performance
9.3.8.3 Product Benchmarking
9.3.8.4 Strategic Initiatives
9.3.9 Enzo Life Sciences, Inc.
9.3.9.1 Company Overview
9.3.9.2 Financial Performance
9.3.9.3 Product Benchmarking
9.3.9.4 Strategic Initiatives
9.3.10 STEMCELL Technologies Inc
9.3.10.1 Company Overview
9.3.10.2 Financial Performance
9.3.10.3 Product Benchmarking
9.3.10.4 Strategic Initiatives
9.3.11 Sino Biological, Inc.
9.3.11.1 Company Overview
9.3.11.2 Financial Performance
9.3.11.3 Product Benchmarking
9.3.11.4 Strategic Initiatives
9.3.12 Abnova Corporation
9.3.12.1 Company Overview
9.3.12.2 Financial Performance
9.3.12.3 Product Benchmarking
9.3.12.4 Strategic Initiatives